Ann: ANP and MCRI new R&D collaboration for ATL1102, page-276

commercially why would you want to offer a drug which is targetting multiple hundreds of thousands of dollar per course for a rare disease for a vaccine side effect treatment (makes it widespread and cheap)?

I thought he was imagining a scenario down the track wherein 1102 could prove to be a more broadly useful anti-inflammatory.

i.e. You're arguing with a point that he wasn't making

That said, at the scale you're talking about (billions of vaccines per annum) + the other ramifications that being more broadly useful might entail (asthma, etc), you don't need to charge hundreds of thousands per treatment.

presumably the drug isnt cheap (by comparison) to manufacture either

Exactly. If the science stacks up, market forces would drive innovation to try and produce it at scale, in a cost effective manner.

Interesting thought experiment though Monti